NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Ironwood Pharmaceuticals, Inc. (IRWD) Stock Analysis

Ironwood Pharmaceuticals, Inc. (IRWD) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

IRWD

$4.26

−$0.03 (−0.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IRWD with… →

IRWD Key Statistics

As of Sep 4, 2026
Trading
Open
$4.26
Previous Close
$4.29
Day's Range
4.22–4.33
52-Week Range
1.05–5.78
Volume
829.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.21
Valuation
Market Cap
$703.92M
P/E Ratio
5.39
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
2.84
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.81
EPS (ttm)Profit attributable to each share over the last twelve months.
0.79
Financials (FY)
Revenue (FY)
$296.15M−15.72%
Net Income (FY)
$24.02M+2629.20%
Profit marginThe share of revenue left as profit after all costs and taxes.
33.36%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
165.24M
1-Year Return
+287.27%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
2.23M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IRWD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.41%
2025−23.93%
2024−61.28%
2023−7.67%
2022+6.26%
2021+2.37%
2020−14.43%
2019+53.40%
2018−30.89%
2017−1.96%
2016 (partial year)+16.54%

As of September 4, 2026.

IRWD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$296.15M$24.02M8.1%
2024$351.41M$880.00K0.3%
2023$442.74M−$1.00B−226.4%
2022$410.60M$175.07M42.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$296.15M—$118.76M$24.02M8.1%
2024$351.41M—$95.72M$880.00K0.3%
2023$442.74M—$168.34M−$1.00B−226.4%
2022$410.60M$410.60M$250.34M$175.07M42.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IRWD Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricIRWDDrug Manufacturers - Specialty & Generic medianvs median
P/E5.3919.270.3x the median
P/S ratio1.812.3021% below
Profit margin33.36%−3.14%36.5 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ironwood Pharmaceuticals, Inc. (IRWD) is capitalised at $703.92M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 100.

IRWD last closed at $4.26 on September 4, 2026. That is −$0.03 (−0.70%) against the previous close. Over the past 52 weeks the price has ranged from $1.05 to $5.78. The latest close sits 305.71% above that 52-week low.

Financial Health

In fiscal 2025, Ironwood Pharmaceuticals, Inc. reported revenue of $296.15M. Against the prior fiscal year total of $351.41M, that is a change of −15.72%. Net income for the same year was $24.02M. That is +2,629.20% against the prior fiscal year. The reported profit margin is 33.36%. That is 36.5 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.79.

Across the 4 fiscal years on file, revenue moves from $410.60M in 2022 to $296.15M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

IRWD trades at a trailing price-to-earnings ratio of 5.39. That is 0.3 times the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 2.84. Measured against sales, the shares trade at 1.81 times revenue. On price-to-sales that is 21.26% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 0.21. Annualized volatility over the trailing 10 years is 61.4%. Over the trailing twelve months the price has returned +287.27%. Across 10 years the annualized return works out at −9.14%.

Growth & Income

No dividend is on file for IRWD.

The strongest complete calendar year on file is 2019 at +53.40%; the weakest is 2024 at −61.28%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +26.41% year to date.

Peer Comparison

Ironwood Pharmaceuticals, Inc. (IRWD) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ironwood Pharmaceuticals, Inc. IRWD $703.92M 5.4
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Ironwood Pharmaceuticals, Inc. trades at a P/E of 5.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Visit website →